Expired activity
Please go to the PowerPak homepage and select a course.

Real-World Issues in HIV Prevention & Treatment:
The Critical Role of the Community Pharmacist

This activity is supported by an educational grant from Gilead Sciences, Inc.

This activity is jointly provided by Global Education Group and Integritas Communications.

In collaboration with The American Academy of HIV Medicine (AAHIVM)

Release date

July 6, 2018

Expiration date

July 6, 2019

Estimated time to complete activity

1.0 hour

Target Audience

The educational design of this activity addresses the needs of clinical pharmacists and other pharmacy staff involved in the care of patients with, or at risk of, human immunodeficiency virus (HIV) infection.

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Describe current HIV epidemiologic trends that inform universal HIV screening, identification of at-risk individuals, HIV prevention strategies, and HIV-care engagement strategies
  • Apply CDC guidelines for identification of individuals at risk for HIV acquisition and determination of preexposure prophylaxis (PrEP) eligibility
  • Demonstrate appropriate antiretroviral therapy (ART)–regimen selection at various stages of HIV treatment, including treatment initiation, treatment failure or viral resistance, and regimen simplification for long-term viral suppression
  • Provide patient education and support for optimized PrEP/ART effectiveness and safety

Statement of Need / Program Description

HIV incidence in the United States has recently declined, while advances in antiretroviral therapy (ART) have improved the longevity and quality of life of many people living with HIV.1,2 Nevertheless, opportunities to expand the capacity for HIV prevention and management abound. The Centers for Disease Control and Prevention (CDC) has issued updated guidance on HIV preexposure prophylaxis (PrEP) for certain high-risk cohorts.3-5sup> Additionally, evidence-based guidelines related to HIV testing and the comprehensive care of HIV-infected patients are updated frequently.6sup> Given the increasingly busy environments of most health care settings, it is not surprising that providers are challenged to stay abreast of the latest best-practice recommendations. Moreover, the resulting gaps in HIV care are often exacerbated by limitations in access to health care. Accessibility and fundamental skill sets make pharmacists well-positioned to improve comprehensive and collaborative efforts for HIV prevention and management.7 In this Evidence-Based Best Practices program, expert faculty will discuss the potential roles of pharmacists in testing for HIV infection, identifying patients who are eligible for PrEP, and selecting ART regimens for individuals living with HIV. The overall goal is to improve the ability of practicing pharmacists to engage in multidisciplinary and longitudinal HIV prevention and treatment strategies.

  1. CDC. CDC Fact Sheet. HIV Incidence: Estimated Annual Infections in the U.S., 2008-2014. Overall and by Transmission Route. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-incidence-fact-sheet_508.pdf. Accessed January 26, 2018..
  2. CDC. Understanding the HIV Care Continuum. 2017. https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf. Accessed January 26, 2018..
  3. CDC. USPHS Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014. https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed January 26, 2017..
  4. Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
  5. Baeten J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410
  6. US Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Updated 2018
  7. 7. Schafer JJ, et al. ASHP guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73(7):468-494


Jennifer CocohobaJennifer Cocohoba, PharmD, BCPS, AAHIVP
Professor of Clinical Pharmacy
University of California San Francisco School of Pharmacy
Pharmacist, UCSF Women’s HIV Program
San Francisco, California

Dr. Jennifer Cocohoba is Professor of Clinical Pharmacy at the University of California, San Francisco (UCSF) School of Pharmacy. Her academic responsibilities include educating health professional students on HIV pharmacotherapy, on monitoring and improving adherence, and on communications skills. A Board-Certified Pharmacotherapy Specialist and American Academy of HIV Medicine–credentialed pharmacist, she also serves as a faculty advisor and research mentor for the UCSF student-run free clinic, the Mabuhay Health Center.

Dr. Cocohoba is the clinical pharmacist for the UCSF Women’s HIV Program (WHP), a novel trauma-informed primary care HIV clinic, where she conducts medication therapy management and HIV regimen consultations, quality improvement initiatives, and research. Her research interests involve antiretroviral pharmacoepidemiology and national guideline concordance, chronic opioid use in persons living with HIV, sex-related HIV treatment disparities, and pharmacy-based interventions to improve medication adherence in underserved populations.

Dan ScalesDan Scales, PharmD
Scales’ Pharmacy
Denver, Colorado

Dr. Dan Scales is the founder and operator of Scales’ Pharmacy in Denver, Colorado. After getting his doctor of pharmacy degree in 2007 from Butler University in Indianapolis, Indiana, he moved to Denver. There he managed community pharmacies for a major chain in environments that ranged from slow suburban neighborhoods to high traffic urban locations. In 2013, Dr. Scales ventured out with an elite, hand-selected team to open a practice focusing on HIV care and prevention, with an emphasis on innovative care delivery and community involvement.

Since the opening of Scales’ Pharmacy, Dr. Scales has been deeply involved with the State of Colorado’s strategy for care and prevention of HIV and sexually transmitted diseases as part of the Colorado AIDS Drug Assistance Program (ADAP) working group. He has also secured the State’s ADAP contract and helped create the pharmacy-based HIV testing programs being developed by the Centers for Disease Control and Prevention.

Elyse TungElyse Tung, PharmD, BCACP
Clinical Assistant Professor
University of Washington School of Pharmacy
Director of Clinical Services
Kelley-Ross Pharmacy at the Polyclinic
Seattle, Washington

Dr. Elyse Tung is the Director of Clinical Services at Kelley-Ross Pharmacy in Seattle, Washington. Since 2009, she has worked on establishing innovative pharmacy practices including the first PrEP clinic managed by a pharmacist in a community pharmacy setting in 2015. Her previous experience also includes establishing a pharmacist-managed anemia clinic, travel clinic, and a transitions-of-care clinic in a senior care center. In 2014 she received the Washington State Pharmacy Association Innovative Pharmacy Practice Award.

Dr. Tung is also a Clinical Assistant Professor at the University of Washington School of Pharmacy. Prior to accepting this position, she completed her pharmacy practice residency at Swedish Medical Center in Seattle, and worked at Overlake Senior Care Center in Bellevue, Washington.

Continuing Pharmacy Education

acpeGlobal Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-18-195-H02-P)

Type of Activity


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Jennifer Cocohoba, PharmD, BCPS, AAHIVP
Has nothing to disclose.

Dan Scales, PharmD
Has nothing to disclose.

Elyse Tung, PharmD, BCACP
Honoraria and Speakers Bureau: Gilead Sciences, Inc.

Planners and Managers

Lindsay Borvansky
Has nothing to disclose.

Andrea Funk
Has nothing to disclose.

Liddy Knight
Has nothing to disclose.

Jim Kappler, PhD
Has nothing to disclose.

Jeanette Ruby, MD
Has nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving credit for this activity. During the period July 6, 2018 through July 6, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.



Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.